NanoMosaic
Private Company
Total funding raised: $105M
Overview
NanoMosaic is a Boston-based private biotech company founded in 2019, commercializing a novel photonics-based platform for multi-omic analysis. Its proprietary NanoNeedle technology, integrated into the 'Tessie' instrument and Nanoplate consumables, offers high-sensitivity, label-free detection with a simple ELISA-like workflow. The company is initially targeting the gene therapy quality control and neurodegenerative disease biomarker markets, positioning itself as a tool provider for research and diagnostic development.
Technology Platform
NanoNeedle photonics platform comprising the 'Tessie' automated plate reader and 'Nanoplate' consumables. Uses silicon nanoneedles for label-free, refractive index-based detection of proteins and nucleic acids from crude samples in a high-throughput, ELISA-like workflow.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
In gene therapy QC, NanoMosaic competes with orthogonal methods like ELISA, qPCR/ddPCR, and AUC, as well as emerging platforms from companies like Gyros Protein Technologies. In proteomics and ultrasensitive immunoassays, key competitors include Quanterix (Simoa), Meso Scale Discovery (MSD), Olink, and traditional mass spectrometry services. Its differentiation lies in its label-free, high-plex photonics approach and simple workflow.